STERIS plc (STE) Financial Ratio Screen

NYSE Healthcare United States USD 23053M
FINANCIAL SCREEN PASSED*
Automated financial screen · activity assessed separately
STERIS plc (STE) passes all available checks in 2 implemented financial-ratio model(s). Its activity assessment is still in progress; this is not a Shariah verdict. Its debt proxy is 19.4% against the model threshold of 30%. The supplied classification is Healthcare (Medical Devices); mixed activities and revenue segments remain part of the activity assessment.

Track STE screening changes

Get an email when this stock's published screening status or underlying ratios change.

MSCI new-inclusion financial-ratio snapshot

STE financial screening at a glance

FINANCIAL SCREEN PASSED*Financial ratios shown separately from business review — not a fatwa
Debt ratio
19.4%
Pass vs 30%
Cash ratio
4.1%
Pass vs 30%
Receivables + cash
14.3%
Pass vs 30%
Impermissible income
0.2%
Pass vs 5%

Calculation date: 2026-08-31. Financial period used: March 2026. The ratios are automated proxies inspired by published methodologies; they are not official index determinations.

Independent method comparison

What the available screens say

How MSCI, FTSE and S&P-style screens differ
Request this stock review
MSCI-styleFinancial criteria passedActivity is assessed separately
FTSE/Yasaar-styleFinancial criteria passedActivity is assessed separately
S&P-style provisionalNot yet availableRequired denominator or financial data is incomplete
Business activityAssessment pendingFinancial results do not determine business permissibility
Complete screening result: not yet completeA complete result requires both supported financial criteria and adequate activity evidence. This site does not issue a fatwa or official index decision.
Financial periodMarch 2026Calculation date2026-08-31S&P-style historynot availableLast activity reviewnot yet reviewed

The request button opens your email application with a pre-filled message. HalalStockGuide receives no address or request unless you choose to send it.

Business activity evidence

Activity assessment in progress

The supplied classification (Medical Devices) is only a starting point. Revenue evidence is being assessed before any complete screening conclusion.

Revenue segments: Not yet checked against an SEC annual filing.

Profile description reviewed: STERIS plc provides infection prevention products and services in the United States, Ireland, and internationally. It operates through three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. The company offers cleaning chemistries and sterility assurance products, automated endoscope reprocessing system and tracking products, endoscopy accessories, instruments, washers, and sterilizers and other pieces of capital equipment, as well as equipment used directly in the procedure rooms, including surgical tables, lights, equipment management services, and connectivity solutions; and various preventive maintenance programs, repair services, custom process improvement consulting, and outsourced instrument sterile processing, as well as instrument, devices, and endoscope repair and maintenance services. It also provides process controls and monitoring systems, as well as integrated sterilization equipment, such as accelerators, product handling, and automation; and sterilization modalities, product development, materials testing, and process validation, as well as support services for sterilization equipment and control systems comprising installation, preventive maintenance, updates, repairs, and troubleshooting. In addition, the company offers pharmaceutical detergents, cleanroom disinfectants and sterilants, pharmaceutical grade and research sterilizers and washers, sterility assurance and maintenance products, vaporized hydrogen peroxide room decontamination systems and sterilizers, and high purity water and pure steam generators; and preventive maintenance programs and repair services to support the operation of capital equipment. It serves healthcare providers, medical device and pharmaceutical manufacturers, biopharmaceutical manufacturing facilities, and hospitals. The company was formerly known as New STERIS Limited and changed its name to STERIS plc in November 2015. STERIS plc was founded in 1985 and is headquartered in Mentor, Ohio.

Sources to verify: Secondary company profile and classification · Issuer website · SEC issuer filings

A sector label or company description can flag a risk but cannot establish a compliant-revenue percentage. Only sourced segment disclosures may support that calculation.

Published-ratio reproductions (not certifications)

The table shows implemented MSCI and FTSE/Yasaar-style asset-based models plus a provisional S&P-style leverage reconstruction where a complete 36-month denominator exists. These are independent calculations, not official index results or Shariah determinations. See formulas, sources and limitations.

Based on financial data from March 2026

Standard Debt Ratio Cash Ratio Receivables Income Status
MSCI 19.4%
/ 30%
4.1%
/ 30%
14.3%
/ 30%
0.17%
/ 5%
FINANCIAL SCREEN PASSED*
FTSE 19.4%
/ 33%
4.1%
/ 33%
14.3%
/ 50%
0.17%
/ 5%
FINANCIAL SCREEN PASSED*

Financial Highlights

P/E Ratio
28.9
Forward: 19.3
EPS
$8.18
Dividend Yield
108.0%
Payout: 30.8%
P/B Ratio
3.2
EV/EBITDA
15.0
EV: $24.6B
Revenue
$5.9B
Growth: 7.3%
Beta
0.9
Average volatility
Current Ratio
1.9

Profitability

Gross Margin 44.4%
Operating Margin 19.2%
Net Margin 13.3%
Return on Equity (ROE) 11.4%
Return on Assets (ROA) 6.8%

Cash Flow & Balance Sheet

Operating Cash Flow$1.3B
Free Cash Flow$972M
Total Debt$2.1B
Debt-to-Equity28.3
Current Ratio1.9
Total Assets$10.7B

Price & Trading

Last Close$237.87
50-Day MA$220.51
200-Day MA$234.17
Avg Volume781K
Beta0.9
52-Week Range
$195.14
$269.44

Financial data provenance and verification

The displayed fields were imported from yfinance on 2026-08-26 for the financial period March 2026. This is a secondary data feed and can differ from amended or newly filed statements.

Verification rule: check debt, cash, receivables, revenue and interest income against the latest primary filing before relying on an automated ratio.

About STERIS plc (STE)

CEO
Mr. Daniel A. Carestio
Employees
17,937
Sector
Healthcare
Industry
Medical Devices
Country
United States
Exchange
NYSE
Market Cap (listing currency)
USD 23053M
Currency
USD

STERIS plc provides infection prevention products and services in the United States, Ireland, and internationally. It operates through three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. The company offers cleaning chemistries and sterility assurance products, automated endoscope reprocessing system and tracking products, endoscopy accessories, instruments, washers, and sterilizers and other pieces of capital equipment, as well as equipment used directly in the procedure rooms, including surgical tables, lights, equipment management services, and connectivity solutions; and various preventive maintenance programs, repair services, custom process improvement consulting, and outsourced instrument sterile processing, as well as instrument, devices, and endoscope repair and maintenance services. It also provides process controls and monitoring systems, as well as integrated sterilization equipment, such as accelerators, product handling, and automation; and sterilization modalities, product development, materials testing, and process validation, as well as support services for sterilization equipment and control systems comprising installation, preventive maintenance, updates, repairs, and troubleshooting. In addition, the company offers pharmaceutical detergents, cleanroom disinfectants and sterilants, pharmaceutical grade and research sterilizers and washers, sterility assurance and maintenance products, vaporized hydrogen peroxide room decontamination systems and sterilizers, and high purity water and pure steam generators; and preventive maintenance programs and repair services to support the operation of capital equipment. It serves healthcare providers, medical device and pharmaceutical manufacturers, biopharmaceutical manufacturing facilities, and hospitals. The company was formerly known as New STERIS Limited and changed its name to STERIS plc in November 2015. STERIS plc was founded in 1985 and is headquartered in Mentor, Ohio.

Popular halal stock checks

Explore other frequently viewed automated stock screens and compare the available financial ratios.

Frequently Asked Questions

Is STERIS plc (STE) halal to invest in?

The current automated result is Financial screen passed; activity assessment pending. It uses available public financial fields and simplified methodology proxies. It is not a fatwa or an official determination by AAOIFI, DJIM, MSCI, S&P, or FTSE.

What is STERIS plc's debt ratio?

STERIS plc's debt ratio is 19.4% in the MSCI new-inclusion reproduction: total debt divided by total assets, against a 30% threshold. See the methodology page for the official source and limitations.

What are STERIS plc's key financial metrics?

STERIS plc has a market capitalization of USD 23053M in its listing currency, trailing P/E ratio of 28.9, and revenue of $5.9B. The company maintains a gross margin of 44.4% and a net margin of 13.3%. Return on equity stands at 11.4%.

How often is the screening data updated?

Calculation date: 2026-08-31. Financial period: March 2026. These dates are shown separately because regenerating this page does not refresh the underlying data.

Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.